BIOCEPT - Key Persons

Job Titles:

• CEO
• Director
• Member of the Audit Committee
• President
• Investor Relations Company Careers Customer Service
• Ivor Royston MD / Independent Director

Mr. Morales is the President, CEO, and a member of the Biocept Board, bringing more than 30 years of broad leadership experience in the US and Latin America. He has served in multiple senior management or consulting roles with various Fortune 100 companies including Citibank, Bank of America, Arthur Andersen, Mazda North America, and McDonald's. Mr. Morales was Business Head of Citibank's consumer finance operation for Latin America and most recently served as president and CEO of Apoyo Financiero, Inc. a Community Development Financial Institution (CDFI). Mr. Morales has led multiple venture capital and private equity backed start-up companies. He earned his Bachelor of Science degree in Finance from the University of Southern California and is a licensed Certified Public Accountant.

Job Titles:

• Certified Public Accountant
• Chairman of the Board
• Member of the Audit Committee
• Member of the Compensation Committee
• Independent Director / Audit Committee

Mr. Gerhardt has been a practicing Certified Public Accountant since 1986. He is also a tax and business advisor providing tax compliance for small businesses and upper income individuals. He earned his Bachelor of Arts Degree from the University of Southern California in 1973 and is a member of the American Institute of Certified Public Accountants. Mr. Gerhardt joined the Biocept Board in 2010 and serves as the board chair. He has extensive experience and expertise in financial, accounting, and tax matters. He is a tax and business advisor for businesses and high net-worth individuals. Prior to joining Biocept, he was a financial vice-president with several companies and also previously worked for KPMG. Mr. Gerhardt is a graduate of the University of Southern California and is a member of the American Institute of Certified Public Accountants.

Job Titles:

• Chief Compliance Officer
• Chief Legal Officer
• Corporate Secretary

Mr. Taylor brings more than 30 years of corporate healthcare and leadership experience, including over 20 years as a transactional healthcare attorney. He is an experienced attorney who has provided legal, regulatory, and compliance counsel to global biopharmaceutical companies, biotech start-ups, and numerous healthcare entities. Most recently, Mr. Taylor served as Chief Compliance Officer and Associate General Counsel for Precision Diagnostics, a privately held company, and its CLIA-certified and CAP-accredited clinical laboratory. Previous to his in-house positions, he honed his skills as an attorney for a decade with the global law firm, DLA Piper, serving Life Science, BioPharma, Private Equity, Venture Capital, and Healthcare-related companies, as well as institutional investors and healthcare providers by assisting them with navigating opportunities in this highly complex, heavily regulated, and ever-changing industry. Mr. Taylor earned his J.D. from the University of Notre Dame Law School and his B.S.M.T., with high honors, at The University of Texas Medical Branch.

Job Titles:

• Scientist
• Vice President, Clinical Development

Dr. Barbara Blouw is a scientist and leads the clinical development for our product pipeline by overseeing activities such as clinical trials, regulatory, and publication strategy. She joined Biocept in 2020 and has led different Investigator Initiated Trials, as well as the development of the FORESEE Study. Barbara brings over 15 years of combined pharma and biotechnology leadership experience. She performed her graduate school research at the University of California San Diego and completed her post-doctoral research at the Sanford Burnham Prebys Medical Research Institute, as a recipient of a fellowship of the California Breast Cancer program. During her work in academic research, she pioneered the development of transgenic mouse models of cancer, particularly for brain tumors. Barbara then transitioned to Navigate BioPharma as an industry professional and oversaw the assay development, validation, and clinical trial testing for a variety of assays, and led the startup for the histopathology lab. Before joining Biocept, she worked at Halozyme Therapeutics where she led multiple clinical and non-clinical collaborations, published multiple peer reviewed publications, and led various regulatory submissions to the FDA and EMA.

Job Titles:

• Chairman
• Member of the Audit Committee
• Member of the Compensation Committee
• Member of the Nominating and Governance Committee
• Chairman of the Science and Technology Committee
• Ivor Royston MD / Independent Director
• Managing Partner of Forward Ventures

Since 1990, Dr. Royston is a founding Managing Partner of Forward Ventures in San Diego, from 1990-2000, he served as founding President and CEO of The Sidney Kimmel Cancer Center and from 1978 to 1990, he was on the oncology faculty of UC, San Diego. In addition to Hybritech, he was a co-founder of IDEC Corporation in 1986, which merged with Biogen to form BiogenIdec. Dr. Royston has been instrumental in the formation, financing and development of numerous biotechnology companies, including: Applied Molecular Evolution (acquired by Eli Lilly); Corixa (acquired by GlaxoSmithKline); Dynavax; Morphotek (acquired by Eisai), Sequana Therapeutics (acquired by Celera); TargeGen (acquired by Sanofi -Aventis), and Triangle Pharmaceuticals (acquired by Gilead). Dr. Royston's recent portfolio investments include HemaQuest, LigoCyte (Chairman), and Syndax. Dr. Royston received his B.A. (1967) and M.D. (1970) degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. In 1997, President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board. Dr. Royston is the chair of Biocept's science and technology committee. He has served as President, Chief Executive Officer, and Director of Viracta since 2015. From 1990 to 2017, Dr. Royston was a Managing Partner of Forward Ventures, a life science venture capital firm. He also previously held the position of Chief Executive Officer of the Sidney Kimmel Cancer Center and was the Director of Clinical Immunology at University of California, San Diego Cancer Center. Dr. Royston was the co-founder of Hybritech, Inc., which developed the PSA test for prostate cancer; and the co-founder of IDEC Corporation, which developed Rituxan, the first approved monoclonal antibody therapy for lymphoma, and which subsequently merged with Biogen to form Biogen Idec, now Biogen. Dr. Royston received his B.A. and M.D. degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University.

Job Titles:

• LHA Investor Relations

Job Titles:

• Chairman of the Compensation Committee
• Independent Director
• Member of the Audit Committee
• Chairman of Biocept 's Compensation Committee
• Independent Director / Chair of the Compensation Committee Member of the Science and Technology Committee
• Member of the Science and Technology Committee

Ms. Rubinstein serves as the chair of Biocept's compensation committee. She is the CFO of Adverum Biotechnologies and consulting CFO of Medikine, and has been a partner at FLG Partners since 2010. She has over 35 years of operational, financial and capital markets experience and has been CFO of numerous public and private companies. While at FLG, Ms. Rubinstein has served as the permanent or interim CFO of Alector, Apexigen, ArmaGen, Five Prime, Ingenuity, iPierian, Kezar, PaxVax, Retrotope, Sublimity, True North and Tunitas, among others. Ms. Rubinstein also has held various positions at life science companies and investment banks, including Solexa, a public genetic analysis instrumentation company, ChemoCentryx, a biotechnology company, RDJ Advisors, a financial and strategic consulting firm, and Lehman Brothers. Ms. Rubinstein received her M.A. and B.A. degrees in Economics from the University of California, Los Angeles.

Job Titles:

• Member of the Audit Committee
• Vice Chair of the Board
• Board Vice Chair and Chair of the Nominating and Corporate Governance Committee
• Executive Vice President / Chief Operating Officer of the Salk Institute for Biological Studies
• Fellow of the Royal Society of Canada
• Independent Director / Audit Committee

Dr. Chandler has been the Executive Vice President/Chief Operating Officer of the Salk Institute for Biological Studies since 2007. She oversees the fiscal and administrative functions of the Institute, providing support to approximately 870 research staff and 230 administrative personnel, and oversees all fund-raising activities. She previously served as Senior Vice Chancellor for Academic Affairs at the University of California, San Diego, where she was the chief academic officer responsible for the policies and decisions relating to all academic programs and faculty appointments and performance. She served as Acting Chancellor from 2003-04 and holds an appointment as Professor of Political Science in the Graduate School of International Relations and Pacific Studies at UCSD. Dr. Chandler is a Fellow of the Royal Society of Canada, the highest academic honor bestowed in that country. She received her Ph.D. from The University of North Carolina at Chapel Hill. Dr. Chandler joined the Biocept Board in 2013 and serves as the board vice chair and chair of the nominating and corporate governance committee. She has extensive experience in organizational management and strategic initiatives. She is Senior Vice Chancellor and Professor Emerita at the School of Global Policy and Strategy at the University of California, San Diego (UCSD). She currently serves as an Advisor to the College of GlobalHealth at Lehigh University, and the Jackson School of Geosciences as well as the College of Pharmaceutical Sciences at the University of Texas at Austin. Dr. Chandler is a member of the Board of Directors of the Corporate Directors Forum. Dr. Chandler previously served as the Executive Vice-President and Chief Operating Officer of the Salk Institute for Biological Studie and as the Senior Vice Chancellor for Academic Affairs at UCSD. Dr. Chandler is a Fellow of the Royal Society of Canada. Dr. Chandler received her Ph.D. from The University of North Carolina at Chapel Hill and has completed the Advanced Management Program at Harvard Business School.

Job Titles:

• Medical Director

Dr. Sweed oversees the medical use of Biocept's technology and laboratory capabilities. He joined Biocept in 2021 to assist in the launch of the CNSide cerebrospinal fluid testing platform. He works closely with our operations, clinical development, and research teams to advise on the medical application, clinical implementation, and execution of Biocept's core technologies. Dr. Sweed is a graduate of the University of Houston (B.S. Biochemical and Biophysical Sciences) and University of Texas Health San Antonio (M.D.). He received post-graduate medical education in anatomic and clinical pathology at University of Texas Southwestern Medical Center and University of Texas Health San Antonio. His medical interests include medical education, patient education, and the advancement of novel and innovative diagnostic methods.

Job Titles:

• Chief Operating Officer

Dr. Marchand is a veteran biotechnology executive and scientist with a proven track record in transitioning concepts to implementation and completion. Most recently, Dr. Marchand was the Chief Operating Officer of Biosplice Therapeutics, aiding in the development of first-in-class small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing. Previously, he was the Chief Information Officer of Genoptix, where he oversaw the creation of the company's diagnostics laboratory, the subsequent IPO, and the acquisition by Novartis. Following the acquisition, he assumed responsibilities for global IT operations for Novartis Oncology. Earlier in his career, Dr. Marchand founded two San Diego-based technology companies, Celula and Parallel Solutions. Dr. Marchand received an MS (Hons), a Ph.D., and the Research Habilitation in Electrical Engineering from the Université de Haute Alsace, France, and was a Lavoisier post-doctoral fellow at the University of California, San Diego.

Job Titles:

• Chairman of the Audit Committee
• Member of the Nominating and Governance Committee
• Chairman of Biocept 's Audit Committee
• Independent Director / Audit Committee
• Independent Director / Chair of the Audit Committee Member of the Nominating and Governance Committee

Ms. Dao-Haddock serves as the chair of Biocept's audit committee. She is currently the Controller of IQHQ, Inc and a member of the Audit and Compliance committee of Sharp Healthcare. She is a certified public accountant (CPA) with more than 20 years of financial and accounting experience including overseeing technical accounting, budgeting, forecasting, financial modeling, cash management, and SEC reporting. Previously, she was Corporate Controller of American Assets Trust, Inc., an NYSE-listed REIT and was Controller at Pacific Corporate Group, LLC, a private equity firm. She began her career at KPMG LLP. Ms. Dao-Haddock received a BS in Business Administration, Accounting from San Diego State University.

Job Titles:

• Controller
• Vice President

Rob Walsh leads our accounting and finance team; he joined the Company in May 2022. He has extensive accounting and finance experience in the biotech and life science space auditing and advising a multitude of enterprises ranging from pre-IPO to large market cap public companies. Before joining the Company, Rob served at PricewaterhouseCoopers LLP ("PWC") within PWC's Health Industries Assurance Practice and at CFGI, an accounting advisory firm. Rob's background includes assurance work as well as assisting companies with drafting and uplifting financial statements to be S-X compliance, preparing technical accounting position papers and overall operational support for the financial statement close process. Rob earned his Bachelor of Science in Accounting and his Master of Science in Accountancy from the University of Rhode Island. Rob is a Certified Public Accountant (CPA).